

2024 Results of Annual General Meeting

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act, PYC Therapeutics Limited (the 'Company') advises that the resolutions contained in the Notice of Meeting dated 14 October 2024 and considered at today's Annual General Meeting of Shareholders were all passed by the required majority following a poll conducted at the meeting. The proxies received in respect of each resolution are set in the attached proxy summary.

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited.

For further information, please contact:

Andrew Taylor

Company Secretary

info@pyctx.com

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing RNA therapeutic class. PYC's drug development programs target monogenic diseases – **the indications with the highest likelihood of success in clinical development**¹.

The Company has multiple ongoing clinical trials and is set to deliver human efficacy data for first-in-class drugs with disease modifying potential across multiple indications within the coming 12 months. The Company's existing drug development pipeline includes four programs addressing indications affecting 1 in every 1,000 people. PYC continues to conduct drug discovery activities to scale its platform technology into additional diseases of the eye, central nervous system, kidney and beyond.

For more information, visit pyctx.com, or follow us on LinkedIn and X.

CONTACTS:
INVESTORS and MEDIA
info@pyctx.com

¹ Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank <https://doi.org/10.1101/2020.11.02.2022232>

Disclosure of Proxy Votes

PYC THERAPEUTICS LIMITED

Annual General Meeting

Wednesday, 13 November 2024

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Remuneration Report	P	997,456,808	941,949,921 94.44%	35,803,287 3.59%	481,000	19,703,600 1.98%	993,248,328 96.52%	35,803,287 3.48%	706,000	-
2 Re-Election of Mr Jason Haddock	P	997,581,808	977,844,107 98.02%	20,017 0.00%	356,000	19,717,684 1.98%	2,616,424,065 100.00%	20,017 0.00%	581,000	Carried
3 Consolidation of Securities	P	968,669,308	944,911,069 97.55%	4,272,172 0.44%	29,268,500	19,486,067 2.01%	2,583,256,025 99.83%	4,272,172 0.17%	29,496,885	Carried

For personal use only